Peking University Cancer Hospital and Institute Exchanges Experience via Poster at 2017 ASCO Annual Meeting
Professor Gu Jin from Peking University Cancer Hospital attended the 2017 Annual Meeting of American Society of Clinical Oncology held in Chicago, USA. He introduced his team’s nationwide pioneering research in non-operative treatment of rectal cancer. That is our country’s first internationally registered clinical trail in wait and see policy with the total relief from radio- and chemo-therapy prior to surgery.
It is learned that rectal cancer is one of the malignant tumors with a fast growing incidence in China. Especially for low rectal cancer, there have been high risks in surgeries and patients’ post-surgery life would be severely affected as well. The findings of Prof Gu Jin’s research showed that wait and see policy, combined with close observations, was feasible and safe to rectal cancer patients. And because the anus and the normal defecation function were reserved, patient life was greatly improved. The research is yet to be perfected so as to demonstrate evidence-based medical proof.
Written by: Lang Lang
Edited by: Liu Xin